Alkahest
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
125 Shoreway Rd Ste D, San Carlos, Calif...Phone Number
(650) 801-0474Website
www.alkahest.comRevenue
$17.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
2
1
1
About Alkahest
Alkahest, a subsidiary of Grifols, is a research and drug discovery company focused on developing transformative therapies through advanced plasma knowledge. Utilizing artificial intelligence and multiomics analysis, they aim to identify early biomarkers of disease linked to changes in plasma proteins. With access to over 100 million plasma samples, Alkahest is positioned to drive breakthroughs in personalized medicine targeting diseases such as Alzheimer's, Parkinson's, and inflammatory conditions. Their innovative approach seeks to inform the development of solutions that enhance patient health and recovery.Explore more
Alkahest Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alkahest your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Alkahest recently announced quarterly report
Product Launch: Get notified when Alkahest launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Alkahest, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Alkahest had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Alkahest
Check if Alkahest has recently received funding, and reach out quickly before it becomes old news!
Check out if Alkahest is spiking on competitors!
Funding: Get notified immidiatlly once Alkahest has new funding data
Recommended Actions
Reach out to Masked Content who joined Alkahest as Masked Content
Find more new buyers
Compare Similar Companies to Alkahest
Compare insights from companies similar to Alkahest, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$23.9M
51-200
Private
$126.7M
2001
SB
Sofia BlehautAssociate Director and Regional Clinical Operations Manager
Company Profile Activity
Activity Insights
Alkahest is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Alkahest is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Alkahest.
Alkahest Tech Stack
A closer look at the technologies used by Alkahest
See more technologies
Most Recent Scoops
Open Position
Open Position
Alkahest is currently seeking a Director Statistical Programming. (San Carlos, CA)
Left Company
Executive Move
Mergers & Acquisitions (M&A)
Alkahest News & Media
Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease
SAN CARLOS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced it will be delivering a presentation of data from a completed study of its therapeutic plasma fraction candidate, GRF6021, in subjects with Parkinson’s disease (PD) and cognitive impairment at the virtual 15th International Conference on Alzheimer’s anAlkahest Announces Peer-Reviewed Publication Demonstrating Safety and Tolerability of GRF6019 in Patients with Mild-to-Moderate Alzheimer’s Disease
GRF6019 was safe and well-tolerated, and patients experienced no cognitive decline and minimal functional decline GRF6019 was safe and well-tolerated, and patients experienced no cognitive decline and minimal functional declineGrifols Moves Deeper Into Proteome R&D With $146M Deal for Alkahest
Alkahest, a company that analyzes blood proteins to develop therapies that address neurological disorders including Alzheimer’s disease, is set to be acquired by partner Grifols in a $146 million deal. Grifols (NASDAQ: GRFS) announced Monday that it is acquiring the shares of privately held Alkahest that it does not already own. Barcelona-based Grifols says the […]Mid-Morning Market Update: Markets Open Lower; Grifols To Buy Geriatric Pharma Startup Alkahest
Following the market opening Tuesday, the Dow traded down 1.75% to 27640.85 while the NASDAQ fell 2.02% to 11084.53. The S&P also fell, dropping 1.73% to 3,367.79. read more
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alkahest
Sign Up For FreeTo access detailed company insights
Alkahest, a subsidiary of Grifols, is a research and drug discovery company focused on developing transformative therapies through advanced plasma knowledge. Utilizing artificial intelligence and multiomics analysis, they aim to identify early biomarkers of disease linked to changes in plasma proteins. With access to over 100 million plasma samples... Read More
